Protekt Therapeutics
PKR Inhibition for Treating Neurodegenerative Diseases
StartupProtekt Therapeutics is a Bnei Brak-based startup in the Health Tech & Life Sciences sector, established in 2014. PKR Inhibition for Treating Neurodegenerative Diseases. The company has raised a total of $13.85M across 4 funding rounds, currently at the Seed stage. Protekt Therapeutics was founded by Prof. Kobi Rosenblum. Key investors include OrbiMed, RMGP Biopharma Investment Fund, Takeda, among 10 total investors. The company has 1-10 employees. Core technologies: Biologicals.
With $13.85M in total funding, Protekt Therapeutics is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQBnei Brak
- Last Round$3.6M
- OrbiMed
- RMGP Biopharma Investment Fund
- Takeda
10 investors total
Prof. Kobi RosenblumInvestor
5 articles covered by sources including www.globes.co.il,
www.timesofisrael.com,
en.globes.co.il,
www.israel21c.org.
What does Protekt Therapeutics do?
Protekt Therapeutics is a biopharmaceutical company aiming to identify and develop a potent and selective oral PKR inhibitor (PKRi) to treat cognitive disorders such as Alzheimers disease and mild cognitive impairment. PKR is a stress and proapoptotic kinase that phosphorylates eIF2, a key protein in the translation machinery, and results in inhibition of protein synthesis and impaired memory consolidation. PKR is also activated during apoptosis, autophagy, neuroinflammation, and A peptide toxicity, which are prominent features of Alzheimer's Disease (AD). Therefore, PKR inhibition offers a novel and promising disease-modifying mechanism for modulating multiple key processes in AD and other neurodegenerative diseases. ProteKt Therapeutics was established in the FutuRx Incubator in December 2015 based on technology from Prof. Kobi Rosenblum's lab (Haifa University) and is now fully owned by Bukwang Pharmaceutical.
How much funding has Protekt Therapeutics raised?
Protekt Therapeutics has raised $13.85M in total funding across 4 rounds. The company is currently at the Seed stage. Key investors include OrbiMed, RMGP Biopharma Investment Fund, Takeda.
Who founded Protekt Therapeutics ?
Protekt Therapeutics was founded in 2014 by Prof. Kobi Rosenblum (Investor).
What sector is Protekt Therapeutics in?
Protekt Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients.
Where is Protekt Therapeutics located?
Protekt Therapeutics is based in Bar Kochva St 16, Bnei Brak, Israel.